(A free translation of the original in Portuguese)

Ouro Fino Saúde Animal Participações S.A. and subsidiaries

Quarterly Information (ITR) at June 30, 2017 and report on review of quarterly information

(A free translation of the original in Portuguese)

Report on review of quarterly information

To the Board of Directors and Stockholders
Ouro Fino Saúde Animal Participações S.A.

Introduction

We have reviewed the accompanying parent company and consolidated interim accounting information of Ouro Fino Saúde Animal Participações S.A. (the "Company"), included in the Quarterly Information Form (ITR) for the quarter ended June 30, 2017, comprising the balance sheet as at that date and the statements of income and comprehensive income for the quarter and six-month period then ended, and the statements of changes in equity and cash flows for the six-month period then ended, and a summary of significant accounting policies and other explanatory information.

Management is responsible for the preparation of the parent company interim accounting information in accordance with the accounting standard CPC 21 (R1) - "Interim Financial Reporting", of the Brazilian Accounting Pronouncements Committee (CPC), and of the consolidated interim accounting information in accordance with CPC 21 (R1) and International Accounting Standard (IAS) 34 - Interim Financial Reporting issued by the International Accounting Standards Board (IASB), as well as the presentation of this information in accordance with the standards issued by the Brazilian Securities Commission (CVM), applicable to the preparation of the Quarterly Information (ITR). Our responsibility is to express a conclusion on this interim financial information based on our review.

Scope of review

We conducted our review in accordance with Brazilian and International Standards on Reviews of Interim Financial Information (NBC TR 2410 - Review of Interim Financial Information Performed by the Independent Auditor of the Entity and ISRE 2410 - Review of Interim Financial Information Performed by the Independent Auditor of the Entity, respectively). A review of interim information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Brazilian and International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion on the interim information

Based on our review, nothing has come to our attention that causes us to believe that the accompanying parent company and consolidated interim accounting information included in the Quarterly Information

PricewaterhouseCoopers, Av. Antônio Diederichsen 400, Ed. Metropolitan Business Center, Ribeirão Preto, SP, Brasil, 14020-250, Caixa Postal 308, T: (16) 3516-6600, F: (16) 3516-6685, www.pwc.com/br

Ouro Fino Saúde Animal Participações S.A.

referred to above has not been prepared, in all material respects, in accordance with CPC 21 (R1) and IAS 34 applicable to the preparation of the Quarterly Information, and presented in accordance with the standards issued by the CVM.

Other matters

Statements of Value Added

We have also reviewed the parent company and consolidated statements of value added for the six-month period ended June 30, 2017. These statements are the responsibility of the Company's management, and are required to be presented in accordance with standards issued by the CVM applicable to the preparation of Quarterly Information (ITR) and are considered supplementary information under IFRS, which do not require the presentation of the statement of value added. These statements were submitted to the same review procedures described above and, based on our review, nothing has come to our attention that causes us to believe that they have not been prepared, in all material respects, in a manner consistent with the parent company and consolidated interim accounting information taken as a whole.

Ribeirão Preto, August 3, 2017

PricewaterhouseCoopers
Auditores Independentes
CRC 2SP000160/O-5 "F"

Maurício Cardoso de Moraes
Contador CRC 1PR035795/O-1 "T" SP

Contents

Interim accounting information

Notes to the interim accounting information

Ouro Fino Saúde Animal Participações S.A.

Balance sheet

All amounts in thousands of reais (A free translation of the original in Portuguese)

		Parent company		Consolidated	
Assets	**Note**	**June 30, 2017**	**December 31, 2016**	**June 30, 2017**	**December 31, 2016**
Current assets					
Cash and cash equivalents	8	21	567	110,069	70,325
Trade receivables	10			115,998	162,478
Inventories	11			131,915	131,303
Taxes recoverable	12			4,393	4,877
Income tax and social contribution recoverable				5,092	5,107
Related parties	27	92	69	366	303
Other assets		19		7,625	5,529
		132	636	375,458	379,922
Non-current assets					
Long-term receivables					
Taxes recoverable	11	113	113	47,172	42,643
Deferred income tax and social contribution	13			16,456	17,081
Related parties	27		165		165
Inventories	11			5,206	
Other assets				2,254	2,806
		113	278	71,088	62,695
Investments in subsidiaries	5	382,908	375,630		
Intangible assets	14			85,317	87,158
Property, plant and equipment	15			246,705	245,801
Total non-current assets		383,021	375,908	403,110	395,654
Total assets		383,153	376,544	778,568	775,576

Balance sheet

All amounts in thousands of reais **(continued)**

		Parent company		Consolidated	
Liabilities and equity	**Note**	**June 30, 2017**	**December 31, 2016**	**June 30, 2017**	**December 31, 2016**
Current liabilities					
Trade payables	16			29,479	23,316
Derivative financial instruments	9			6,421	8,820
Borrowings	17			97,169	73,550
Salaries and social charges		137	114	23,713	17,299
Taxes payable		56	55	2,938	4,053
Income tax and social contribution payable				567	1,056
Related parties	27	36	41	127	355
Commissions on sales				3,908	6,070
Other liabilities		7		6,024	8,440
Total current liabilities		236	210	170,346	142,959
Non-current liabilities					
Derivative financial instruments	9			5,577	10,584
Borrowings	17			216,347	241,888
Provision for contingencies	18			3,529	3,850
Total non-current liabilities				225,453	256,322
Total liabilities		236	210	395,799	399,281
Equity	19				
Share capital		358,796	299,107	358,796	299,107
Capital reserve		(6,392)	(6,392)	(6,392)	(6,392)
Options granted		3,731	3,076	3,731	3,076
Revenue reserves		5,346	65,035	5,346	65,035
Carrying value adjustments		15,220	15,508	15,220	15,508
Retained earnings		6,216		6,216	
		382,917	376,334	382,917	376,334
Non-controlling interests				(148)	(39)
Total equity		382,917	376,334	382,769	376,295
Total liabilities and equity		383,153	376,544	778,568	775,576

The accompanying notes are an integral part of this quarterly information.

Ouro Fino Saúde Animal Participações S.A.

Statement of income
Periods ended June 30, 2017 and 2016
All amounts in thousands of reais unless otherwise stated (A free translation of the original in Portuguese)

		Parent company			
			2017		2016
	Note	Quarter	6-month period	Quarter	6-month period
General and administrative expenses	22	(761)	(1,340)	(919)	(1,487)
Equity in the results of investees	5	13,867	7,529	5,363	2,569
Other income, net	23	15	36	20	39
Operating profit		13,121	6,225	4,464	1,121
Finance income			14	1	14
Finance costs		(11)	(23)	(11)	(21)
Finance result	24	(11)	(9)	(10)	(7)
Profit for the period		13,110	6,216	4,454	1,114

The accompanying notes are an integral part of this quarterly information.

Ouro Fino Saúde Animal Participações S.A.

Statement of income
Periods ended June 30, 2017 and 2016
All amounts in thousands of reais unless when otherwise stated

					Consolidated
			2017		2016
	Note	Quarter	6-month period	Quarter	6-month period
Revenue	20	137,932	213,118	134,591	232,621
Cost of sales	21	(67,269)	(102,722)	(65,659)	(111,540)
Gross profit		70,663	110,396	68,932	121,081
Selling expenses	21	(40,174)	(75,381)	(43,674)	(87,173)
General and administrative expenses	21	(10,159)	(20,798)	(12,245)	(21,675)
Other income (expenses), net	22	2,030	2,474	(282)	(467)
Operating profit		22,360	16,691	12,731	11,766
Finance income		1,805	3,103	747	1,622
Finance costs		(4,370)	(8,433)	(2,649)	(5,290)
Derivative financial instruments, net		2,641	(3,061)	(11,760)	(22,354)
Foreign exchange variations, net		(2,842)	(232)	6,854	14,576
Finance result	23	(2,766)	(8,623)	(6,808)	(11,446)
Profit before income tax and social contribution		19,594	8,068	5,923	320
Income tax and social contribution	24				
Current		(594)	(1,326)	(234)	(2,954)
Deferred		(5,961)	(625)	(1,263)	3,694
Profit for the period		13,039	6,117	4,426	1,060
Attributable to:					
Owners of the parent		13,110	6,216	4,454	1,114
Non-controlling interests		(71)	(99)	(28)	(54)
		13,039	6,117	4,426	1,060
Earnings per share attributable to owners of the parent during the period (in reais)	25				
Basic earnings per share		0.24301	0.11522	0.08257	0.02065
Diluted earnings per share		0.24423	0.11589	0.08225	0.02059

The accompanying notes are an integral part of this quarterly information.

Ouro Fino Saúde Animal Participações S.A.

Statement of comprehensive income
Periods ended June 30, 2017 and 2016
All amounts in thousands of reais (A free translation of the original in Portuguese)

				Parent company
		2017		2016
	Quarter	6-month period	Quarter	6-month period
Profit for the period	13,110	6,216	4,454	1,114
Other comprehensive income				
Items that will be reclassified to profit or loss				
Exchange variation of investment in subsidiary located abroad	(182)	(288)	(318)	(473)
Total comprehensive income for the period	12,928	5,928	4,136	641

				Consolidated
		2017		2016
	Quarter	6-month period	Quarter	6-month period
Profit for the period	13,039	6,117	4,426	1,060
Other comprehensive income				
Items that will be reclassified to profit or loss				
Exchange variation of investment in subsidiary located abroad	(189)	(298)	(331)	(495)
Total comprehensive income for the period	12,850	5,819	4,095	565
Attributable to:				
Owners of the parent	12,928	5,928	4,136	641
Non-controlling interests	(78)	(109)	(41)	(76)
	12,850	5,819	4,095	565

The accompanying notes are an integral part of this quarterly information.

Ouro Fino Saúde Animal Participações S.A.

Statement of changes in equity

All amounts in thousands of reais (A free translation of the original in Portuguese)

		Attributable to owners of the parent									
					Revenue reserves						
	Note	Share capital	Capital reserve	Options granted	Legal reserve	Profit retention reserve	Carrying value adjustments	Retained earnings	Total	Non-controlling interests	Total equity
At January 1, 2016		298,889	(6,392)	1,491	5,346	64,895	15,952		380,181	128	380,309
Comprehensive income for the period											
Profit for the period								1,114	1,114	(54)	1,060
Exchange variation of subsidiary located abroad	5						(473)		(473)	(22)	(495)
Total comprehensive income for the period							(473)	1,114	641	(76)	565
Contributions by owners											
Stock options granted	19 (e)			863					863		863
Total contributions by owners				863					863		863
At June 30, 2016		298,889	(6,392)	2,354	5,346	64,895	15,479	1,114	381,685	52	381,737
At January 1, 2017		299,107	(6,392)	3,076	5,346	59,689	15,508		376,334	(39)	376,295
Comprehensive income for the period											
Profit for the period								6,216	6,216	(99)	6,117
Exchange variation of subsidiary located abroad	5						(288)		(288)	(10)	(298)
Total comprehensive income for the period							(288)	6,216	5,928	(109)	5,819
Contributions by owners											
Capital increase by incorporation of revenue reserves	19 (a)	59,689				(59,689)					
Stock options granted	19 (e)			655					655		655
Total contributions by owners		59,689		655		(59,689)			655		655
At June 30, 2017		358,796	(6,392)	3,731	5,346		15,220	6,216	382,917	(148)	382,769

The accompanying notes are an integral part of this quarterly information.

Ouro Fino Saúde Animal Participações S.A.

Statement of cash flows
Six-month period ended June 30
All amounts in thousands of reais (A free translation of the original in Portuguese)

	Note	Parent company 2017	Parent company 2016	Consolidated 2017	Consolidated 2016
Cash flows from operating activities					
Profit before income tax and social contribution		6,216	1,114	8,068	320
Adjustments for:					
Provision for impairment of trade receivables	10			148	5,773
Provision for inventory losses and write-offs	11			7,024	1,298
Reversal of the provision for sales returns	18			(2,863)	
Provision for bonuses to customers	18			(780)	606
Equity in the results of investees	5	(7,529)	(2,569)		
Depreciation and amortization	14 and 15			12,417	10,738
Provision for impairment of intangible assets	14			(279)	111
Reversal of the provision for discounts on sales of vaccines against foot-and-mouth disease	18			(2,443)	(1,985)
Result on disposal of property, plant and equipment	22			(52)	(44)
Result on disposal of intangible assets	22			(1,476)	481
Interest and monetary and exchange variations, net				8,262	(12,382)
Derivative financial instruments				3,061	22,354
Provision for contingencies	18			(320)	258
Stock options granted	19 (e)	8	11	655	863
Changes in working capital					
Trade receivables				52,163	28,054
Inventories				(11,657)	(32,818)
Taxes recoverable			84	(4,049)	(5,633)
Other assets		123	(74)	256	3,413
Trade payables				5,076	18,126
Taxes payable		1	(494)	(1,127)	(946)
Other liabilities		25	193	2,408	(1,384)
Cash provided by (used in) operations		(1,156)	(1,735)	74,492	37,203
Interest paid				(6,837)	(5,380)
Income tax and social contribution paid				(1,695)	(5,250)
Net cash provided by (used in) operating activities		(1,156)	(1,735)	65,960	26,573
Cash flows from investing activities					
Advances for future capital increase	5	(18,565)			
Investments in intangible assets	14			(8,335)	(9,283)
Purchases of property, plant and equipment	15			(7,733)	(19,593)
Receipts of dividends and interest on capital	5	19,175	17,714		
Proceeds from sale of property, plant and equipment				618	935
Proceeds from sale of intangible assets				4,254	
Net cash provided by (used in) investing activities		610	17,714	(11,196)	(27,941)
Cash flows from financing activities					
Proceeds from borrowings				39,950	59,857
Repayment of borrowings				(44,494)	(38,223)
Payment of dividends and interest on capital			(16,433)		(16,433)
Realized derivative financial instruments				(10,466)	(2,887)
Net cash provided by (used in) financing activities			(16,433)	(15,010)	2,314
Net increase (decrease) in cash and cash equivalents		(546)	(454)	39,754	946
Cash and cash equivalents at the beginning of the period	8	567	468	70,325	23,380
Exchange losses on cash and cash equivalents				(10)	(1,101)
Cash and cash equivalents at the end of the period	8	21	14	110,069	23,225

The accompanying notes are an integral part of this quarterly information.

Ouro Fino Saúde Animal Participações S.A.

Statement of value added
Six-month period ended June 30
All amounts in thousands of reais (A free translation of the original in Portuguese)

	Parent company		Consolidated	
	2017	2016	2017	2016
Revenues				
Gross sales and services			233,858	257,801
Other income			2,591	(96)
Income related to the construction of own assets			7,700	6,740
Provision for impairment of trade receivables			(148)	(5,773)
			244,001	258,672
Inputs acquired from third parties				
Cost of sales and services			(73,085)	(88,650)
Materials, electricity, third-party services and other	(462)	(725)	(61,850)	(64,072)
Losses on assets, net			(6,310)	(1,479)
	(462)	(725)	(141,245)	(154,201)
Gross value added (distributed)	(462)	(725)	102,756	104,471
Depreciation and amortization			(12,417)	(10,738)
Net value added (distributed) generated by the entity	(462)	(725)	90,339	93,733
Value added received through transfer				
Equity in the results of investees	7,529	2,569		
Finance income	14	14	4,719	22,067
Royalties	50	50	50	50
Other			167	184
Total value added distributed	7,131	1,908	95,275	116,034
Distribution of value added				
Personnel				
Direct compensation	737	630	45,404	49,399
Benefits	2	4	8,849	9,856
Government Severance Indemnity Fund for Employees (FGTS)			4,738	3,826
Taxes, charges and contributions				
Federal	150	134	16,324	15,652
State	3	5	(1,341)	(45)
Municipal			135	195
Remuneration of third parties' capital				
Interest, foreign exchange variation, losses on derivatives, etc.	23	21	13,356	33,702
Rentals			1,577	1,979
Other			116	410
Remuneration of own capital				
Profits reinvested	6,216	1,114	6,216	1,114
Non-controlling interests			(99)	(54)
Value added distributed	7,131	1,908	95,275	116,034

The accompanying notes are an integral part of this quarterly information.

All amounts in thousands of reais unless when otherwise stated

Section A - General information

1.1 Operations

Ouro Fino Saúde Animal Participações S.A. (the "Company") is a listed corporation headquartered in the city of Cravinhos, state of São Paulo. The Company's shares are traded on the São Paulo Futures, Commodities and Securities Exchange - BM&FBovespa S.A. ("BM&FBovespa") in the Novo Mercado (New Market) category.

The Company and its subsidiaries (together the "Group") operate in the animal health industry, specifically in the development, production and sale of veterinary drugs, vaccines and other products for production and companion animals.

At the Extraordinary General Meeting held on August 31, 2016, the stockholders approved the merger of General Atlantic Ouro Fino Participações S.A. ("GAOF"), based on an appraisal report at book value as of June 30, 2016, issued by independent appraisers on August 12, 2016.

On October 20, 2014, GAOF, the investment holding company, acquired approximately 14.27% of the Company's capital for R$ 200,000, resulting in goodwill based on expected future profitability (under the terms of Law 9,532/97) of R$ 160,097, as described below:

Equity of Ouro Fino Saúde Animal Participações S.A. at September 30, 2014	227,784
Capital increase by issue of shares (IPO)	51,923
(a) Equity of Ouro Fino Saúde Animal Participações S.A. adjusted for determination of goodwill	279,707
(b) Interest acquired by General Atlantic Ouro Fino Participações S.A.	14.27%
(b) Equity acquired by General Atlantic Ouro Fino Participações S.A. (a x b)	39,903
(d) Amount paid	200,000
(e) Goodwill generated in the transaction (d - c)	160,097
(f) Tax benefit ((e) x 34%)	54,433

As provided for in CVM Instructions 319/99, 349/01 and 565/15, for purposes of downstream merger, the goodwill initially recorded by GAOF was reduced to the limit of the tax benefit expected from the likely future reduction in the Company's taxes.

After the merger, and considering that the realization of the tax benefit arising from the goodwill is not currently expected, management decided to record a provision in the full amount of the merged balance, with a corresponding entry in the same line item of the special goodwill reserve on merger where the benefit was initially recorded. In this context, there was no impact on the consolidated accounting information.

The issue of this parent company and consolidated interim accounting information was authorized by the Company's Board of Directors on August 3, 2017.

1.2 Basis of preparation

The parent company and consolidated interim accounting information has been prepared in accordance with accounting practices adopted in Brazil, including the pronouncements issued by the Brazilian Accounting Pronouncements Committee (CPC), as well as according to the International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board (IASB), and present all (and only) the significant information that is inherent to the accounting information, which is consistent with that used by management in its activities.

The main accounting policies applied in the preparation of this interim accounting information are set out in Note 29.

The interim accounting information was prepared in accordance with the Brazilian Technical Pronouncement CPC 21 - Interim Financial Reporting, and with International Accounting Standard IAS 34 - Interim Financial Reporting, issued by the International Accounting Standards Board (IASB), and is presented in accordance with the standards issued by the Brazilian Securities Commission (CVM) applicable to the preparation of Quarterly Information (ITR).

The preparation of interim accounting information requires the use of certain critical accounting estimates. It also requires management to exercise its judgment in the process of applying the accounting policies. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to the parent company and consolidated interim accounting information, are disclosed in Note 2.

(a) Parent company accounting information

The parent company accounting information has been prepared in accordance with accounting practices adopted in Brazil issued by the Brazilian Accounting Pronouncements Committee (CPC). Because the accounting practices adopted in Brazil applicable to individual financial information, as from 2014, do not differ from the International Financial Reporting Standards (IFRS) applicable to separate financial information, which now allow entities to use the equity method to account for investments in subsidiaries in the separate financial statements, they are also in compliance with the IFRS issued by the International Accounting Standards Board (IASB), and are disclosed together with the consolidated accounting information.

(b) Consolidated accounting information

The consolidated financial information has been prepared and is being presented in accordance with accounting practices adopted in Brazil, including the pronouncements issued by the Brazilian Accounting Pronouncements Committee (CPC), as well as according to the International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board (IASB).

The presentation of the parent company and consolidated statements of value added is required by the Brazilian corporate legislation and the accounting practices adopted in Brazil for listed companies, The International Financial Reporting Standards (IFRS) do not require the presentation of this statement. Therefore, under the IFRS, the presentation of such statement is considered supplementary information, and not part of the set of accounting information.

1.3 Changes in accounting policies and disclosures

In the six-month period ended June 30, 2017 and in the year ended December 31, 2016, there were no amendments to existing standards or interpretations which could have a material effect on the Group's accounting information.

1.4 Consolidation

The Company consolidates all entities which it controls, as described in Note 5 (b), in accordance with the description in Note 29.1.

Section B - Risks

2 Critical accounting estimates and judgments

Critical accounting estimates and judgments are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Based on assumptions, the Group makes estimates concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and judgements that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are addressed below.

(a) Fair value of derivative financial instruments

The fair value of derivative financial instruments is determined by using valuation techniques. The Group uses judgment to select among a variety of methods and make assumptions that are mainly based on market conditions existing at the end of each reporting period.

(b) Provision for impairment of trade receivables

Impairment is established when there is objective evidence that the companies will not be able to recover all the amounts due. The calculation of the provision is based on a reasonable estimate to cover probable losses on the realization of receivables, taking into consideration the situation of each customer and respective guarantees.

(c) Deferred income tax and social contribution

The deferred income tax and social contribution assets, arising from income tax and social contribution losses, were recognized based on the expectation of future realization, supported by projections of results made by management, which consider the typical development of business and markets, according to the currently known scenarios.

(d) Impairment of property, plant and equipment

The recovery capacity of the assets that are used in the Group's activities is evaluated whenever events or changes in circumstances indicate that the carrying amount of an asset or a group of assets may not be recoverable based on future cash flows. If the carrying amount of these assets is higher than their recoverable value, the net value is adjusted and the useful lives revised to new levels.

(e) Provision for contingencies

The Group companies are parties to tax, labor and civil litigation at various court levels. Provisions for contingencies, to cover expected losses on proceedings in progress, are established and updated based on management's assessment, according to the opinion of its legal counsel, and require a high level of judgment on the matters involved.

(f) Fair value of the stock option plan

The fair value attributed to the options granted was determined using the Black-Scholes-Merton pricing model, which takes into consideration the value of the share, the exercise price, the time to elapse up to the exercise of the option, the likelihood of the option to be exercised, the historical volatility, the dividend rate and the risk-free interest rate.

(g) Impairment of intangible assets

The Group annually tests product development balances in intangible assets for impairment, whenever possible through the discounted cash flow method, considering, among other aspects:

(i) Assumptions of future revenue generation, based on market size (current and estimated) and on the Group's expected market share;

(ii) Estimates of direct and indirect manufacturing costs; and

(iii) Trading expenditures, such as marketing, commission, freight and storage expenses.

The projection period covers five or more years as from the estimated launching date, depending on the estimates of the product's life cycle, market development and level of associated technological innovation. Provisions are recorded when the recoverable amount (net present value of cash flow) is below the amount of the recorded asset, pursuant to the Company's accounting policy presented in Note 29.8.

(h) Provision for adjustment of the prices adopted in sales of vaccines against foot-and-mouth disease

Considering the high competitiveness in the market of vaccines against foot-and-mouth disease and in line with market practices in which price negotiations can be extended up to the beginning of the following vaccination campaign period, the Group assesses the FMD vaccine market conditions on a quarterly basis, and determines, based on its experience, accumulated knowledge of the sector, public information on this market and the projected demand of its customer portfolio, if the need exists to adjust the prices charged. When an adjustment in the prices of FMD vaccines is required, it is recorded by reducing the net sales amount in the statement of income with a corresponding entry in trade receivables.

3 Financial risk management

3.1 Financial risk factors

The activities of the Group companies expose them to financial risks mainly related to foreign exchange variations, fluctuation in interest rates, credit and liquidity. The objective of risk management is to reduce potential unexpected variations in the results arising from the aforementioned risks. The Group manages financial risks as the basis for its growth strategy and satisfactory cash flows. The Group has a Finance Committee that establishes management strategies regarding such exposures, which could include the utilization of derivative or non-derivative financial instruments for hedging potential risks.

The Group monitors the levels of exposure to each market risk (foreign exchange variation and interest rate) through an analysis based on accounting exposure and future cash flow projections.

(a) Market risks

(i) Foreign exchange risk

This risk arises from the possibility of the Group incurring unexpected losses due to fluctuations in foreign exchange rates which reduce the amount of assets and increase liabilities. The Group is mainly exposed to the fluctuation in the U.S. dollar exchange rate.

In order to protect from foreign exchange risks, when necessary, the Group utilizes derivative transactions, mainly exchange rate swap.

Swaps, classified as derivatives at fair value through profit or loss, were contracted to exchange the charges on borrowings initially obtained in foreign currency for charges based on the Interbank Deposit Certificate (CDI) rate variation. Gains and losses are recognized in "Finance income and costs" in the statement of income.

All amounts in thousands of reais unless when otherwise stated

The following table presents the consolidated accounting balances of the assets and liabilities denominated in U.S. dollars:

	June 30, 2017	December 31, 2016
Assets in foreign currency		
Cash and cash equivalents	984	2,251
Trade receivables	8,586	7,504
Advances to suppliers	9,653	855
	19,223	10,610
Liabilities in foreign currency		
Trade payables	15,885	12,229
Advances from customers	67	
	15,952	12,229
Net exposure - assets (liabilities)	3,271	(1,619)

Assets and liabilities denominated in foreign currency are regularly monitored through estimated cash flows of inflows and outflows related to foreign exchange assets and liabilities. The amount of assets and liabilities in foreign currency fluctuates during a year, which may or may not cause a mismatch. Consequently, in order to mitigate risks arising from any possible foreign exchange variations, whenever required, derivative transactions may be contracted.

The table does not present balances of borrowings for working capital purposes in foreign currency amounting to R$ 75,882 (December 31, 2016 - R$ 96,224) (Note 17), because they are hedged by foreign exchange swap.

In the table below five scenarios are presented, considering the changes in the quotation of the Brazilian real (R$) against the U.S. dollar (US$).

		Impact of the appreciation/depreciation of the U.S. dollar on the portfolio balance					
		3.31	3.37	2.53	1.69	4.21	5.06
Assets/liabilities	**Risk**	**June 30, 2017**	**Scenario 1**	**Scenario 2**	**Scenario 3**	**Scenario 4**	**Scenario 5**
			(probable)	(US$ depreciation - 25%)	(US$ depreciation - 50%)	(US$ appreciation - 25%)	(US$ appreciation - 50%)
Cash and cash equivalents	US$ depreciation	984	18	(251)	(501)	251	501
Trade receivables	US$ depreciation	8,586	160	(2,187)	(4,373)	2,187	4,373
Advances to suppliers	US$ depreciation	9,653	180	(2,458)	(4,917)	2,458	4,917
Trade payables	US$ appreciation	15,885	(297)	4,045	8,091	(4,045)	(8,091)
Advances from customers	US$ appreciation	67	(1)	17	34	(17)	(34)

(ii) Interest rate risk

This risk arises from the possibility that the Group may incur losses due to adverse fluctuations in interest rates. The Group's interest rate risk primarily arises from borrowings. Indebtedness is mainly subject to the fixed interest rates and the Interbank Deposit Certificate (CDI) rate. The Group seeks to maintain a stable relation between its long and short-term indebtedness, maintaining a higher proportion in the long-term. As regards financial investments, the index is the CDI rate.

The Group continuously monitors market interest rates in order to assess the need to contract new derivatives to hedge against the volatility risk of these rates.

The Group believes that currently there is a balance between fixed interest rates, which represent 55.0% (December 31, 2016 - 50.0%) and variable interest rates, which represent 45.0% (December 31, 2016 - 50.0%) of its borrowings, providing mitigation in risks associated with any fluctuations in interest rates.

(b) Credit risk

The Group is potentially subject to credit risk related to trade receivables, financial investments and derivatives. To limit the risk associated with financial assets, especially financial investments and derivatives contracts, the Group carries out transactions only with prime financial institutions.

The credit risk is mitigated through a broad customer base and careful selection of customers by business segment (production animals and companion animals), in addition to the utilization of guarantees, establishment of individual exposure limits and a well-defined credit policy that utilizes credit risk modeling, through which a rating and credit risk level is attributed to each customer, based on the Group's 30 years of experience in the market.

The Group has a Credit Committee that establishes guidelines and assesses and monitors the levels of credit risk that the Group is willing to accept in the course of its business.

In addition to the risk mitigations established in credit policies, the Group has credit insurance coverage contracted for a portion of its sales.

The Group classifies its customers' portfolio through risk evaluation methodologies developed internally, with the purpose of properly assessing the real risk of its customers. Weights are attributed to each variable, including the history of payments, length of the business relationship with the Group, period during which the company has been operating in the market and other variables, and a rating is defined for each customer based on their combination. This classification is defined according to ratings ranging from "AA" (the lowest risk) to "E" (the highest risk) (Note 7).

All amounts in thousands of reais unless when otherwise stated

(c) Liquidity risk

The Group adopts a responsible policy for managing its financial assets and liabilities, which is monitored by the Chief Financial Officer through operating strategies to ensure liquidity, profitability and security.

Cash flow forecasting is based on the approved budget and subsequent adjustments, which takes into consideration, besides all the operating plans, the plan for raising funds to support planned investments and the maturity schedule of the debts. The treasury area monitors daily the forecasts included in the cash flow projections to ensure the Group has sufficient cash to meet operational needs. Additionally, the Group has previously approved credit facilities available to increase and strengthen its liquidity position.

Cash and cash equivalents are primarily invested in Repurchase Agreements, corresponding to highly liquid instruments.

The Group maintains its gearing ratio in a manner that does not jeopardize its payment capacity and investments. As established by a guideline, the highest percentage of indebtedness should be allocated to the long-term.

The table below analyzes the financial liabilities into relevant maturity groupings, based on the remaining period between the balance sheet date up to the contractual maturity date.

The amounts disclosed in the table are the contractual undiscounted cash flows.

				Consolidated
	Less than 1 year	**From 1 to 2 years**	**From 2 to 5 years**	**Over 5 years**
At June 30, 2017				
Trade payables	29,479			
Borrowings (*)	107,642	128,812	71,856	43,848
Derivative financial instruments, net	6,421	5,577		
Other liabilities	37,277	1,058	2,471	
	180,819	135,447	74,327	43,848
At December 31, 2016				
Trade payables	23,316			
Borrowings (*)	92,980	161,332	63,419	38,304
Derivative financial instruments, net	8,820	10,584		
Other liabilities	37,273	1,155	2,695	
	162,389	173,071	66,114	38,304

(*) As the amounts included in the table are the contractual undiscounted cash flows, and therefore include future financial charges, these amounts will not reconcile to the amounts disclosed on the balance sheet for borrowings.

All amounts in thousands of reais unless when otherwise stated

3.2 Capital management

The Group's objectives when managing capital are to safeguard its ability to continue as a going concern in order to provide returns for stockholders, maintain a strong credit classification in order to support business and maximize value for the stockholders.

The Group manages the capital structure and adjusts it considering changes in the economic situation. The capital structure arises from the selection between own capital (capital contributions and profit retention) and third-party capital to finance the Group's operations. The Group monitors capital on the basis of the gearing ratio, which can be measured using several indexes.

The gearing ratios at June 30, 2017 and December 31, 2016 are as follows:

		Consolidated	
	Note	**June 30, 2017**	**December 31, 2016**
Borrowings	17	313,516	315,438
Derivative financial instruments, net	9	11,998	19,404
Cash and cash equivalents	8	(110,069)	(70,325)
Net debt		215,445	264,517
Equity	19	382,769	376,295
Total capital		598,214	640,812
Gearing ratio (%)		36.01	41.28

3.3 Fair value estimation

The fair value of the financial instruments contracted by the Group is measured based on information obtained from the financial institutions and prices quoted in an active market based on the standard market pricing methodology, which comprises measuring their nominal value up to the due date and discounting this to present value at future market rates.

The Group assesses, at the balance sheet date, whether there is objective evidence that a financial asset or a group of financial assets is impaired in relation to its recoverable value.

The carrying amounts of trade receivables, less provision for impairment, and trade payables are assumed to approximate their fair values, especially considering term and nature. The fair value of financial liabilities for disclosure purposes is estimated by discounting the future contractual cash flows at the current market interest rate that is available to the Group for similar financial instruments.

Financial instruments are measured in the balance sheet at fair value; this requires disclosure of fair value measurements by level of hierarchy.

All the Group's financial instruments have been classified as Level 2 "Other observable significant data", as shown below.

		Consolidated	
As per balance sheet	**Classification**	**June 30, 2017**	**December 31, 2016**
Liabilities - Derivative financial instruments			
Exchange rate swap	Level 2	11,998	19,404

Section C - Segment reporting

4 Segment reporting

The Board of Directors is the chief decision-maker and has determined the operating segments based on strategic business decisions. The segments are:

- Production animals - sale in the domestic market of veterinary drugs, vaccines and other products for cattle, pigs, poultry, sheep, horses and goats.
- Companion animals - sale in the domestic market of veterinary drugs and other products for dogs and cats.
- International operations - sale in the foreign market, mainly to Latin American countries, of veterinary drugs, vaccines and other products for production and companion animals.

The manufacture of the products takes place at the Company's industrial facilities in the city of Cravinhos, state of São Paulo.

Sales are widely dispersed and, therefore, there are no customers representing more than 10% of net revenue.

Assets and liabilities, general and administrative expenses, other income (expenses), net, finance income and costs and income tax and social contribution are analyzed on a joint basis and, therefore, are not presented by business segment.

All amounts in thousands of reais unless when otherwise stated

The results by segment are as follows:

	Quarter ended June 30, 2017			
	Business segment			
	Production animals	Companion animals	International operations	Total
Revenue	106,522	14,358	17,052	137,932
Cost of sales	(54,282)	(4,061)	(8,926)	(67,269)
Gross profit	52,240	10,297	8,126	70,663
Selling expenses	(28,951)	(6,227)	(4,996)	(40,174)
Result - Segmented	**23,289**	**4,070**	**3,130**	**30,489**
Result - Not segmented				(17,450)
Profit for the period				13,039

	Six-month period ended June 30, 2017			
	Business segment			
	Production animals	Companion animals	International operations	Total
Revenue	160,333	30,737	22,048	213,118
Cost of sales	(83,025)	(8,806)	(10,891)	(102,722)
Gross profit	77,308	21,931	11,157	110,396
Selling expenses	(53,757)	(12,787)	(8,837)	(75,381)
Result - Segmented	**23,551**	**9,144**	**2,320**	**35,015**
Result - Not segmented				(28,898)
Profit for the period				6,117

	Quarter ended June 30, 2016			
	Business segment			
	Production animals	Companion animals	International operations	Total
Revenue	105,814	17,625	11,152	134,591
Cost of sales	(57,991)	(4,384)	(3,284)	(65,659)
Gross profit	47,823	13,241	7,868	68,932
Selling expenses	(33,697)	(5,758)	(4,219)	(43,674)
Result - Segmented	**14,126**	**7,483**	**3,649**	**25,258**
Result - Not segmented				(20,832)
Profit for the period				4,426

	Six-month period ended June 30, 2016			
	Business segment			
	Production animals	Companion animals	International operations	Total
Revenue	180,585	31,726	20,310	232,621
Cost of sales	(96,415)	(8,202)	(6,923)	(111,540)
Gross profit	84,170	23,524	13,387	121,081
Selling expenses	(64,815)	(11,470)	(10,888)	(87,173)
Result - Segmented	**19,355**	**12,054**	**2,499**	**33,908**
Result - Not segmented				(32,848)
Profit for the period				1,060

All amounts in thousands of reais unless when otherwise stated

The breakdown, by country, of revenues from international operations is as follows:

	2017		2016	
	Quarter	6-month period	Quarter	6-month period
Colombia	2,780	5,383	2,336	4,070
Mexico	3,006	4,815	3,855	6,608
Ecuador	838	1,422	578	912
Paraguay	3,836	3,836	1,688	4,430
Bolivia	2,237	2,237	885	1,305
Other	4,355	4,355	1,810	2,985
	17,052	22,048	11,152	20,310

Section D - Group structure

5 Investments (parent company)

(a) Information on the investments

Name	Country	Business	Direct holding	Indirect holding
(i) Ouro Fino Saúde Animal Ltda.	Brazil	Research, development, production and sale of veterinary drugs, vaccines and other products. Sales in the domestic market are carried out through the companies mentioned in items (ii) and (iii) below. Sales in the foreign market are carried out directly with third parties and through the companies mentioned in items (iv) and (v) below. This company also provides manufacturing services to order from third parties.	99.99%	
(ii) Ouro Fino Agronegócio Ltda.	Brazil	Sales in the domestic market of veterinary drugs, vaccines and other products for production animals purchased from the company mentioned in item (i) and from third parties.	99.99%	
(iii) Ouro Fino Pet Ltda.	Brazil	Sales in the domestic market of veterinary drugs and products and related goods for companion animals purchased from the company mentioned in item (i) and from third parties.	99.99%	
(iv) Ouro Fino de México, S.A. de CV	Mexico	Sales, exclusively in Mexico, of veterinary drugs and other products purchased from the company mentioned in item (i).		96.43%
(v) Ouro Fino Colômbia S.A.S	Colombia	Sales, exclusively in Colombia, of veterinary drugs and other products purchased from the company mentioned in item (i).		100.00%

All amounts in thousands of reais unless when otherwise stated

(b) Changes in investments

	Parent company	
	June 30, 2017	June 30, 2016
Opening balance	375,630	391,110
Equity in the results of investees	7,529	2,569
Payment of capital with advances for future capital increase (ii)	18,565	
Stock options granted	647	852
Dividends received (i)	(19,175)	(13,005)
Foreign exchange variation of foreign investments	(288)	(473)
Closing balance	382,908	381,053

(i) In the six-month period ended June 30, 2017, the quotaholders of the subsidiary Ouro Fino Pet Ltda. approved the distribution of dividends to the parent company Ouro Fino Saúde Animal Participações S.A. in the amount of R$ 19,175 (in the six-month period ended June 30, 2016, the quotaholders of the subsidiaries Ouro Fino Saúde Animal Ltda., Ouro Fino Agronegócio Ltda. and Ouro Fino Pet Ltda. approved the distribution of dividends in the amounts of R$ 3,455, R$ 419 and R$ 9,131, respectively).

(ii) At June 30, 2017, the quotaholders of the subsidiary Ouro Fino Saúde Animal Ltda. approved the payment of capital with advances for future capital increase totaling R$ 18,565, and capital was increased from R$ 218,874 to R$ 237,439.

All amounts in thousands of reais unless when otherwise stated

(c) Summarized financial information

Set out below is the summarized financial information for subsidiaries.

(i) Summarized balance sheet

	June 30, 2017				
	Subsidiaries				
	Direct			Indirect	
	Ouro Fino Saúde Animal Ltda.	Ouro Fino Agronegócio Ltda.	Ouro Fino Pet Ltda.	Ouro Fino de México, S.A. de C.V.	Ouro Fino Colômbia S.A.S
Current					
Assets	220,859	170,117	23,050	9,254	6,689
Liabilities	(119,538)	(64,252)	(4,555)	(13,355)	(8,748)
Current assets (liabilities), net	101,321	105,865	18,495	(4,101)	(2,059)
Non-current					
Assets	367,245	21,386	502	976	854
Liabilities	(208,768)	(9,841)	(172)	(1,039)	(1,094)
Non-current assets (liabilities), net	158,477	11,545	330	(63)	(240)
Equity (net capital deficiency)	259,798	117,410	18,825	(4,164)	(2,299)

	December 31, 2016				
	Subsidiaries				
	Direct			Indirect	
	Ouro Fino Saúde Animal Ltda.	Ouro Fino Agronegócio Ltda.	Ouro Fino Pet Ltda.	Ouro Fino de México, S.A. de C.V.	Ouro Fino Colômbia S.A.S
Current					
Assets	212,238	197,623	32,541	10,631	5,911
Liabilities	(101,916)	(84,874)	(4,217)	(12,148)	(6,887)
Current assets (liabilities), net	110,322	112,749	28,324	(1,517)	(976)
Non-current					
Assets	358,535	24,233	714	430	833
Liabilities	(226,313)	(17,970)	(360)		(1,094)
Non-current assets (liabilities), net	132,222	6,263	354	430	(261)
Equity (net capital deficiency)	242,544	119,012	28,678	(1,087)	(1,237)

All amounts in thousands of reais unless when otherwise stated

(ii) Summarized statement of income

	Quarter ended June 30, 2017				
	Subsidiaries				
	Direct			Indirect	
	Ouro Fino Saúde Animal Ltda.	Ouro Fino Agronegócio Ltda.	Ouro Fino Pet Ltda.	Ouro Fino de México, S.A. de C.V.	Ouro Fino Colômbia S.A.S
Net sales revenue	84,754	101,823	15,229	3,006	2,781
Profit (loss) before income tax and social contribution	7,134	6,611	4,673	(1,998)	(605)
Income tax and social contribution	(3,059)	(2,220)	(593)		
Profit (loss) for the period	4,075	4,391	4,080	(1,998)	(605)

	Six-month period ended June 30, 2017				
	Subsidiaries				
	Direct			Indirect	
	Ouro Fino Saúde Animal Ltda.	Ouro Fino Agronegócio Ltda.	Ouro Fino Pet Ltda.	Ouro Fino de México, S.A. de C.V.	Ouro Fino Colômbia S.A.S
Net sales revenue	136,121	151,270	32,423	4,815	5,384
Profit (loss) before income tax and social contribution	(726)	(2,626)	10,602	(2,781)	(1,073)
Income tax and social contribution	(822)	947	(1,325)		14
Profit (loss) for the period	(1,548)	(1,679)	9,277	(2,781)	(1,059)

	Quarter ended June 30, 2016				
	Subsidiaries				
	Direct			Indirect	
	Ouro Fino Saúde Animal Ltda.	Ouro Fino Agronegócio Ltda.	Ouro Fino Pet Ltda.	Ouro Fino de México, S.A. de C.V.	Ouro Fino Colômbia S.A.S
Net sales revenue	76,641	105,111	18,368	3,854	2,336
Profit (loss) before income tax and social contribution	409	(523)	6,967	(761)	(325)
Income tax and social contribution	(1,012)	201	(737)		81
Profit (loss) for the period	(603)	(322)	6,230	(761)	(244)

All amounts in thousands of reais unless when otherwise stated

	Six-month period ended June 30, 2016				
	Subsidiaries				
	Direct			Indirect	
	Ouro Fino Saúde Animal Ltda.	Ouro Fino Agronegócio Ltda.	Ouro Fino Pet Ltda.	Ouro Fino de México, S.A. de C.V.	Ouro Fino Colômbia S.A.S
Net sales revenue	138,070	176,362	33,324	6,607	4,070
Profit (loss) before income tax and social contribution	(9,789)	(232)	12,001	(1,160)	(912)
Income tax and social contribution	2,038	92	(1,320)	(338)	154
Profit (loss) for the period	(7,751)	(140)	10,681	(1,498)	(758)

(iii) Statement of comprehensive income

	2017		2016	
	Quarter	6-month period	Quarter	6-month period
Ouro Fino Saúde Animal Ltda. (direct subsidiary)				
Profit (loss) for the period	4,075	(1,548)	(603)	(7,751)
Other comprehensive income (loss)	(182)	(288)	(318)	(473)
Total comprehensive income (loss)	3,893	(1,836)	(921)	(8,224)

(iv) Summarized statement of cash flows

	June 30, 2017				
	Subsidiaries				
	Direct			Indirect	
	Ouro Fino Saúde Animal Ltda.	Ouro Fino Agronegócio Ltda.	Ouro Fino Pet Ltda.	Ouro Fino de México, S.A. de C.V.	Ouro Fino Colômbia S.A.S
Cash flows from operating activities					
Cash provided by (used in) operating activities	39,065	25,441	14,319	(3,420)	(1,379)
Interest paid	(5,468)	(712)		(388)	(269)
Income tax and social contribution paid			(1,695)		
Net cash provided by (used in) operating activities	33,597	24,729	12,624	(3,808)	(1,648)
Net cash provided by (used in) investing activities	(13,226)	3,159	(1)	(484)	(61)
Net cash provided by (used in) financing activities	6,733	(8,133)	(19,175)	4,348	1,645
Net increase (decrease) in cash and cash equivalents	27,104	19,755	(6,552)	56	(64)
Cash and cash equivalents at the beginning of the period	48,636	8,725	10,872	996	530
Exchange losses on cash and cash equivalents	(10)				
Cash and cash equivalents at the end of the period	75,730	28,480	4,320	1,052	466

All amounts in thousands of reais unless when otherwise stated

	June 30, 2016				
	Subsidiaries				
	Direct			Indirect	
	Ouro Fino Saúde Animal Ltda.	Ouro Fino Agronegócio Ltda.	Ouro Fino Pet Ltda.	Ouro Fino de México, S.A. de C.V.	Ouro Fino Colômbia S.A.S
Cash flows from operating activities					
Cash provided by (used in) operating activities	9,705	26,433	10,117	(6,123)	(949)
Interest paid	(4,209)	(1,157)			(14)
Income tax and social contribution paid		(3,962)	(713)	(575)	
Net cash provided by (used in) operating activities	5,496	21,314	9,404	(6,698)	(963)
Net cash used in investing activities	(27,588)	(1,556)	(289)	(171)	(20)
Net cash provided by (used in) financing activities	19,024	(15,930)	(9,132)	7,071	1,437
Net increase (decrease) in cash and cash equivalents	(3,068)	3,828	(17)	202	454
Cash and cash equivalents at the beginning of the period	10,820	5,155	5,263	1,370	305
Exchange gains on cash and cash equivalents	(1,065)	(35)	(1)		
Cash and cash equivalents at the end of the period	6,687	8,948	5,245	1,572	759

(d) Reconciliation of financial information of investments

	Subsidiaries							
	Ouro Fino Saúde Animal Ltda.		Ouro Fino Agronegócio Ltda.		Ouro Fino Pet Ltda.		Total	
	2017	2016	2017	2016	2017	2016	2017	2016
Equity at January 1	242,544	249,003	119,012	125,384	28,678	23,646	390,234	398,033
Profit (loss) for the period	(1,548)	(7,751)	(1,679)	(140)	9,277	10,681	6,050	2,790
Capital increase with advances for future capital increase	18,565							
Stock options granted	525	719	77	93	45	40	647	852
Distribution of dividends and interest on capital		(3,455)		(420)	(19,175)	(9,130)	(19,175)	(13,005)
Foreign exchange variation of foreign investments	(288)	(473)					(288)	(473)
Equity at June 30	259,798	238,043	117,410	124,917	18,825	25,237	396,033	388,197
Percentage holding (%)	99.99%	99.99%	99.99%	99.99%	99.99%	99.99%		
Share of investments	259,798	238,043	117,410	124,917	18,825	25,237	396,033	388,197
Unrealized profit in inventories	(13,125)	(7,144)					(13,125)	(7,144)
Carrying amount of the investment in the parent company	246,673	230,899	117,410	124,917	18,825	25,237	382,908	381,053

All amounts in thousands of reais unless when otherwise stated

Section E - Selected significant notes

6 Financial instruments by category

	June 30, 2017		December 31, 2016	
	Parent company	Consolidated	Parent company	Consolidated
	Loans and receivables	Loans and receivables	Loans and receivables	Loans and receivables
Assets as per balance sheet				
Cash and cash equivalents	21	110,069	567	70,325
Accounts receivable		115,998		162,478
Related parties	92	366	234	468
Other assets, except for prepaid expenses		6,893		5,826
	113	233,326	801	239,097

	June 30, 2017			December 31, 2016		
	Parent company		Consolidated	Parent company		Consolidated
	Other financial liabilities	Liabilities at fair value through profit or loss	Other financial liabilities	Other financial liabilities	Liabilities at fair value through profit or loss	Other financial liabilities
Liabilities as per balance sheet						
Trade payables			29,479			23,316
Derivative financial instruments		11,998			19,404	
Borrowings			313,516			315,438
Related parties	36		127	41		355
Commissions on sales			3,908			6,070
Other liabilities	7		6,024			8,440
	43	11,998	353,054	41	19,404	353,619

7 Credit quality of financial assets

The credit quality of financial assets that are neither past due nor impaired is assessed by reference to external credit ratings (if available) or to historical information about counterparty default rates.

The balances of bank current accounts and financial investments amounting to R$ 110,021 (December 31, 2016 - R$ 70,281) are held in prime financial institutions rated as BB by Standard & Poor's.

All amounts in thousands of reais unless when otherwise stated

The balances of trade receivables are evaluated as described in Note 3.1 (b), as follows:

	Consolidated	
	June 30, 2017	December 31, 2016
AA	28,645	49,077
A	54,103	67,022
B	14,453	24,731
C	8,737	11,687
D	9,376	8,547
E	7,358	7,891
	122,672	168,955

8 Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and at banks, as well as investments consisting of repurchase agreements and CDBs earning on average up to 98.5% of the Interbank Deposit Certificate (CDI) rate.

	Parent company		Consolidated	
	June 30, 2017	December 31, 2016	June 30, 2017	December 31, 2016
Cash				
In local currency			6	6
In foreign currency			42	38
			48	44
Banks				
In local currency	21	14	1,859	1,973
In foreign currency			942	2,213
	21	14	2,801	4,186
Financial investments				
In local currency				
Repurchase agreements		553	56,241	44,084
Bank Deposit Certificates (CDB)			50,979	22,011
		553	107,220	66,095
	21	567	110,069	70,325

All amounts in thousands of reais unless when otherwise stated

9 Derivative financial instruments (consolidated)

	June 30, 2017	December 31, 2016
	Liabilities	Liabilities
Exchange rate swap contracts	11,998	19,404
Non-current	(5,577)	(10,584)
Current	6,421	8,820

The notional amounts of the exchange rate swap contracts at June 30, 2017 were US$ 22,500 thousand (December 31, 2016 - US$ 28,961 thousand).

10 Trade receivables (consolidated)

	June 30, 2017	December 31, 2016
In local currency	113,411	156,205
In foreign currency	9,261	12,750
Provision for impairment of trade receivables	(6,674)	(6,477)
Current	115,998	162,478

The analysis of the maturity of trade receivables is as follows:

	June 30, 2017	December 31, 2016
Falling due		
Up to 3 months	91,085	120,635
From 3 to 6 months	15,166	32,321
Over 6 months	425	2,640
	106,676	155,596
Past due		
Up to 3 months	7,171	5,582
From 3 to 6 months	1,134	2,582
Over 6 months	7,691	5,195
	15,996	13,359
	122,672	168,955

All amounts in thousands of reais unless when otherwise stated

The analysis of the provision for impairment of trade receivables is made individually for each customer and, as a general rule, was established for receivables overdue for more than 180 days and without guarantees. Management maintains the appropriate collection procedures in relation to the other overdue receivables and believes that the Group will not incur losses. Changes in the provision were as follows:

	June 30, 2017	June 30, 2016
Opening balance	6,477	2,760
Additions	394	5,887
Reversal	(246)	(114)
Foreign exchange variation	49	(388)
Closing balance	6,674	8,145

The additions to and release of the provision for impaired receivables have been included in "Selling expenses" in the statement of income (Note 21). The amounts are generally written off from the provision account when there is no expectation of recovering the funds.

11 Inventories (consolidated)

	June 30, 2017	December 31, 2016
Finished products	84,889	81,728
Raw materials	29,474	36,861
Packaging materials	9,887	10,551
Work in progress	7,829	5,292
Imports in transit	5,699	231
Advances to suppliers (*)	9,774	876
Other	5,760	5,532
Provision for inventory losses (Note 18)	(16,191)	(9,768)
Non-current (*)	(5,206)	
Current	131,915	131,303

(*) Refers to a loan agreement between the subsidiary Ouro Fino Saúde Animal Ltda. and the supplier Laboratório Biomega S.A. ("Biomega"). The settlement of the related amount will take place upon the delivery of the goods within 36 months.

All amounts in thousands of reais unless when otherwise stated

12 Taxes recoverable

	Parent company		Consolidated	
	June 30, 2017	December 31, 2016	June 30, 2017	December 31, 2016
ICMS			46,857	42,506
ICMS, PIS and COFINS on acquisitions of property, plant and equipment			1,194	1,488
IRRF	113	113	1,027	670
IPI			346	342
PIS and COFINS			725	711
Other			1,416	1,803
	113	113	51,565	47,520
Non-current	(113)	(113)	(47,172)	(42,643)
Current			4,393	4,877

ICMS credits, which amounted to R$ 46,347 at June 30, 2017 (December 31, 2016 - R$ 41,604) were substantially generated by Ouro Fino Saúde Animal Ltda. and are not subject to monetary restatement. These credits are generated by exempted sales in domestic and foreign transactions and by sales with a sixty-percent reduction in the calculation basis in interstate transactions, with the full/partial maintenance of credits on inputs, pursuant to the ICMS Agreement 100/97.

After the rural funding files under the Coordinating Committee of Tax Administration Board (CAT) Ordinance 83/2009 are filed and approved by the tax authorities, the credit balances are converted into accumulated credits to be appropriated according to applicable legislation and, therefore, may be utilized in the purchase of inputs and machinery and equipment and/or transferred to other Group companies with which there is an interdependence relationship and which regularly calculate ICMS payable. Currently, Ouro Fino Saúde Animal Ltda. has been filing, on a retroactive basis, rural funding files (CAT Ordinance 83/2009), which must be submitted in chronological order to enable the transformation of the credit balance into accumulated credit, thus allowing its use as described above.

ICMS credits related to 2010, 2011, 2012 and 2013 amounting to R$ 18,846 were approved by the tax authorities, and R$ 11,048 was released for immediate use. The residual balance of R$ 7,798 was temporarily withheld in relation to tax assessment notices which have been discussed at an administrative level and obligations related to the submission of electronic files under the terms of the Coordinating Committee of Tax Administration Board (CAT) Ordinance 83/2009. Up to June 30, 2017, all released credits had already been used.

The credit balance accounted for corresponds to the residual value of the years 2010 to 2013 relating to amounts withheld and to all the credit balance of years 2014, 2015 and 2016; the requests for accumulated credits will be made by submitting the related file through the Electronic System for Management of the Accumulated Credit (e-CredAc), under the terms of the CAT Ordinance 83/2009, which have been consistently prepared by management on the dates established in law.

In this context, the Company's management understands that there is no risk of not realizing the amounts recorded; therefore, no provision for impairment of these receivables is necessary.

All amounts in thousands of reais unless when otherwise stated

13 Current and deferred income tax and social contribution (consolidated)

The Company and its subsidiaries Ouro Fino Saúde Animal Ltda. and Ouro Fino Agronegócio Ltda. determine income tax and social contribution on the taxable profit method, calculated at the rates of 25% for income tax and 9% for social contribution, whereas Ouro Fino Pet Ltda. adopts the deemed profit method. The companies located in Mexico and Colombia calculate their taxes based on the regulations of those countries. Therefore, there is no direct correlation between the amounts presented in the consolidated statement of income and the results that would have been obtained by applying the standard rates mentioned above.

Deferred tax credits related to income tax and social contribution arise substantially from temporary differences.

(a) Composition, nature and realization of deferred taxes

(i) Deferred income tax and social contribution

	June 30, 2017	December 31, 2016
Tax credits on:		
Accumulated income tax and social contribution losses	2,660	792
Tax benefit of goodwill merged (Note 1.1)	54,433	54,433
Provision for the possible non-use of tax benefit of goodwill merged (Note 1.1)	(54,433)	(54,433)
Temporary differences		
Provisions	11,727	12,308
Unrealized profit in inventories	6,761	7,524
Pre-operating expenses written-off	672	768
Derivative financial instruments	4,079	6,597
Appreciation - business combination	708	695
	26,607	28,684
Tax liabilities on:		
Temporary differences		
Deemed cost of land	(7,878)	(7,878)
RD&I incentive - Accelerated depreciation	(325)	
Foreign exchange variations - cash basis	(1,948)	(3,725)
	(10,151)	(11,603)
Total assets, net	16,456	17,081
Total deferred tax credits	26,607	28,684
Total deferred tax liabilities	10,151	11,603

The deferred income tax and social contribution are presented net, by entity, in the balance sheet.

All amounts in thousands of reais unless when otherwise stated

The net changes in the deferred tax account were as follows:

	June 30, 2017	June 30, 2016
Opening balance	17,081	5,558
Pre-operating expenses written-off	(96)	(96)
Accumulated income tax and social contribution losses	1,868	653
Derivative financial instruments	(2,518)	6,619
Provisions	(581)	1,182
Unrealized profit in inventories	(763)	114
Foreign exchange variations - cash basis	1,777	(5,252)
RD&I benefit - Accelerated depreciation	(325)	
Appreciation - business combination	13	402
Closing balance	16,456	9,180

The amounts by estimated offset years are as follows:

	June 30, 2017	December 31, 2016
Deferred tax assets to be recovered		
within 1 year	22,792	23,398
from 2 to 5 years	3,815	5,286
	26,607	28,684
Deferred tax liabilities to be settled		
within 1 year	2,273	3,725
after 5 years	7,878	7,878
	10,151	11,603

14 Intangible assets (consolidated)

	At January 1, 2016	Additions	Provision for impairment	Foreign exchange variation	Transfer to inventories	Amortization	At June 30, 2016
Goodwill on the acquisition of subsidiaries	618						618
Trademarks and licenses purchased	677	2		(31)		(438)	210
Development and registration of products	57,577	8,037	(111)		(481)	(1,849)	63,173
Computer software	18,554	1,244				(2,558)	17,240
Other	1,264					(135)	1,129
	78,690	9,283	(111)	(31)	(481)	(4,980)	82,370

All amounts in thousands of reais unless when otherwise stated

	At January 1, 2017	Additions	Provision for impairment	Foreign exchange variation	Transfer to inventories	Write-offs	Amortization	At June 30, 2017
Goodwill on the acquisition of subsidiaries	618							618
Trademarks and licenses purchased	36	43		24			(37)	66
Development and registration of products	69,055	8,081	279	14	(1,361)	(3,040)	(2,766)	70,262
Computer software	16,456	211					(3,155)	13,512
Other	993						(134)	859
	87,158	8,335	279	38	(1,361)	(3,040)	(6,092)	85,317

	June 30, 2017			
	Cost	Provision for impairment	Accumulated amortization	Net
Goodwill on the acquisition of subsidiaries	618			618
Trademarks and licenses purchased	3,183		(3,117)	66
Development and registration of products	94,687	(4,683)	(19,742)	70,262
Computer software	32,924		(19,412)	13,512
Other	1,333		(474)	859
	132,745	(4,683)	(42,745)	85,317

	December 31, 2016			
	Cost	Provision for impairment	Accumulated amortization	Net
Goodwill on the acquisition of subsidiaries	618			618
Trademarks and licenses purchased	3,116		(3,080)	36
Development and registration of products	92,018	(4,962)	(18,001)	69,055
Computer software	32,714		(16,258)	16,456
Other	1,333		(340)	993
	129,799	(4,962)	(37,679)	87,158

The development and registration of products substantially refer to expenditures incurred for new drugs amounting to R$ 70,262 (December 31, 2016 - R$ 69,055). The amortization of intangible assets related to product development and registration was recognized within "Cost of sales" (Note 21).

The assumptions utilized to analyze evidence of impairment are disclosed in Note 29.8.

All amounts in thousands of reais unless when otherwise stated

15 Property, plant and equipment (consolidated)

	At January 1, 2016	Additions	Foreign exchange variation	Transfers	Write-offs	Depreciation	At June 30, 2016
	24,985						24,985
Buildings and improvements	74,099	89		90	(111)	(1,092)	73,075
Machinery, equipment and industrial facilities	61,392	3,265		2,710	(31)	(2,727)	64,609
Vehicles and tractors	4,863	2,539	(107)	410	(749)	(904)	6,052
Furniture and fittings	2,920	179	(3)	11		(281)	2,826
IT equipment	3,565	387	(4)	17	(6)	(623)	3,336
Construction in progress (i)	19,700	13,066		(2,800)	(48)		29,918
Other	2,571	68	(15)	(438)	(136)	(131)	1,919
	194,095	19,593	(129)		(1,081)	(5,758)	206,720

	At January 1, 2017	Additions	Foreign exchange variation	Transfers	Write-offs	Depreciation	At June 30, 2017
Land	24,985						24,985
Buildings and improvements	80,849			46,218		(1,404)	125,663
Machinery, equipment and industrial facilities	78,732	992		5,336	(150)	(3,138)	81,772
Vehicles and tractors	4,998		56		(380)	(760)	3,914
Furniture and fittings	2,989	393	2		(11)	(303)	3,070
IT equipment	2,725	33	2		(24)	(569)	2,167
Construction in progress (i)	48,598	6,164		(51,491)			3,271
Other	1,926	151		(63)		(151)	1,863
	245,802	7,733	60		(565)	(6,325)	246,705

	At June 30, 2017			At December 31, 2016			
	Cost	Accumulated depreciation	Net	Cost	Accumulated depreciation	Net	Annual average depreciation rates
Land	24,985		24,985	24,985		24,985	
Buildings and improvements	143,028	(17,365)	125,663	96,810	(15,961)	80,849	2.30%
Machinery, equipment and industrial facilities	121,749	(39,977)	81,772	116,235	(37,503)	78,732	5.55%
Vehicles, tractors and aircraft	7,335	(3,421)	3,914	7,726	(3,137)	4,589	19.23%
Furniture and fittings	7,335	(4,265)	3,070	7,084	(4,107)	2,977	7.98%
IT equipment	9,878	(7,711)	2,167	9,883	(7,176)	2,707	10.77%
Construction in progress (i)	3,271		3,271	48,598		48,598	
Other	3,921	(2,058)	1,863	4,272	(1,908)	2,364	8.03%
	321,502	(74,797)	246,705	315,593	(69,792)	245,801	

(j) The balance of construction in progress substantially comprises the residual balance of the construction of the new plant of biological products (vaccines) amounting to R$ 1,968 (December 31, 2016 - R$ 45,337).

The amounts related to operating and financial lease are not significant.

At June 30, 2017, borrowing costs totaling R$ 725 (December 31, 2016 - R$ 693) were capitalized, at an average rate of 4.19% (December 31, 2016 - 4.23%).

Land, buildings, machinery and equipment amounting to R$ 87,939 (December 31, 2016 - R$ 89,537) are pledged as collaterals for borrowings (Note 17).

All amounts in thousands of reais unless when otherwise stated

16 Trade payables (consolidated)

	June 30, 2017	December 31, 2016
In local currency	13,594	11,087
In foreign currency	15,885	12,229
	29,479	23,316

17 Borrowings (consolidated)

	Financial charges incurred	Final Maturity	June 30, 2017	December 31, 2016
In foreign currency				
Export credit note	Exchange variation and weighted average rate of 4.65% p.a.	2017		8,365
Working capital	Exchange variation and weighted average rate of 3.01% p.a. (December 31, 2016 - 3.06% p.a.)	2019	75,882	87,859
In local currency				
FINEP (Technological innovation)	Weighted average rate of 4.19% p.a. (December 31, 2016 - 4.23% p.a.)	2024	149,513	165,385
BNDES	Weighted average rate of 11.73% p.a.	2025	28,003	
BNDES - EXIM	Weighted average rate of 11.19% p.a. (December 31, 2016 - 12.47% p.a.)	2018	39,175	38,339
BNDES - FINAME	Weighted average rate of 6.42% p.a. (December 31, 2016 - 6.67% p.a.)	2023	994	1,270
Working capital (i)	Mexican Interbank Equilibrium Interest Rate (TIIE) + 1.5% p.a.	2018	10,719	6,160
Working capital (i)	Depósito a Término Fijo (DTF) + 3.5% p.a.	2018	7,105	5,454
Finance leasing	Weighted average rate of 13.47% p.a. (December 31, 2016 - 15.45% p.a.)	2019	2,125	2,606
			313,516	315,438
Current			(97,169)	(73,550)
Non-current			216,347	241,888

(i) Borrowings obtained by the subsidiaries Ouro Fino de México, S.A de C.V in Mexican pesos and Ouro Fino Colômbia S.A.S in Colombian pesos.

(a) Guarantees for borrowings

The borrowings for research, innovation and development of products obtained from the Fund for Financing of Studies and Projects (FINEP) are guaranteed by a surety of the related parties Ouro Fino Participações e Empreendimentos S.A., Ouro Fino Saúde Animal Participações S.A. and bank guarantees totaling R$ 50,695, in addition to the guarantee represented by the industrial facilities of animal health products located in the city of Cravinhos, state of São Paulo. No amounts are charged for the guarantees given.

All amounts in thousands of reais unless when otherwise stated

Borrowings for purposes of working capital and leases are collaterized by sureties of the parent company and/or controlling stockholders. Borrowings from the Government Agency for Machinery and Equipment Financing (FINAME) are guaranteed through the statutory lien of the assets financed, in addition to sureties of the parent company and/or controlling stockholders.

The carrying amounts of borrowings approximate their fair values.

The maturity of non-current borrowings is as follows:

	June 30, 2017	December 31, 2016
From 1 to 2 years	110,729	146,166
From 2 to 3 years	21,848	23,623
From 3 to 4 years	21,622	17,738
From 4 to 5 years	21,617	17,644
Over 5 years	40,531	36,717
	216,347	241,888

(b) Working capital borrowings in foreign currency

Exchange rate swap transactions were contracted for borrowings for working capital purposes contracted in foreign currency (US$), which amounted to R$ 75,882 (December 31, 2016 - R$ 96,224), to exchange the charges on the borrowings for charges based on the CDI rate (Note 9).

All amounts in thousands of reais unless when otherwise stated

18 Provisions (consolidated)

	Quarter ended June 30, 2017				
	Opening balance	Additions	Reversals	Foreign exchange variation	Closing balance
Sales returns	4,424	577	(2,945)		2,056
Discounts on sales of vaccines against foot-and-mouth disease	1,523		(1,523)		
Bonuses on products	569		(569)		
Contingencies	4,088	79	(624)	(13)	3,530
Provision for impairment of intangible assets	4,962		(279)		4,683
Provision for impairment of trade receivables	6,527	206	(107)	48	6,674
Provision for inventory losses	14,219	4,149	(2,176)	(1)	16,191
	36,312	5,011	(8,223)	34	33,134

	Six-month period ended June 30, 2017				
	Opening balance	Additions	Reversals	Foreign exchange variation	Closing balance
Sales returns	4,919	1,790	(4,653)		2,056
Discounts on sales of vaccines against foot-and-mouth disease	2,443	141	(2,584)		
Bonuses on products	780	295	(1,075)		
Contingencies	3,850	688	(1,008)		3,530
Provision for impairment of intangible assets	4,962		(279)		4,683
Provision for impairment of trade receivables	6,477	394	(246)	49	6,674
Provision for inventory losses	9,768	8,947	(2,523)	(1)	16,191
	33,199	12,255	(12,368)	48	33,134

	Quarter ended June 30, 2016				
	Opening balance	Additions	Reversals	Foreign exchange variation	Closing balance
Discounts on sales of vaccines against foot-and-mouth disease	3,214	1,783	(3,259)		1,738
Bonuses on products	1,798	1,227	(2,419)		606
Contingencies	3,825	327	(101)	(87)	3,964
Provision for impairment of intangible assets	1,396				1,396
Provision for impairment of trade receivables	6,021	1,372	1,065	(313)	8,145
Provision for inventory losses	2,497	1,097	(532)		3,062
	18,751	5,806	(5,246)	(400)	18,911

	Six-month period ended June 30, 2016				
	Opening balance	Additions	Reversals	Foreign exchange variation	Closing balance
Discounts on sales of vaccines against foot-and-mouth disease	3,723	1,783	(3,768)		1,738
Bonuses on products		3,025	(2,419)		606
Contingencies	3,841	408	(150)	(135)	3,964
Provision for impairment of intangible assets	1,285	111			1,396
Provision for impairment of trade receivables	2,760	5,773		(388)	8,145
Provision for inventory losses	1,806	2,040	(784)		3,062
	13,415	13,140	(7,121)	(523)	18,911

All amounts in thousands of reais unless when otherwise stated

(a) Product returns and discounts on sales of vaccines against foot-and-mouth disease

The Group recognizes a provision for cases of customers entitled to return the product in a given period. Revenue is adjusted by the expected value of the returns and the cost of sales is adjusted by the value of the corresponding goods to be returned. The Group also recognizes a provision for adjustment of prices adopted in sales of foot-and-mouth disease vaccines, according to Note 2 (h).

(b) Bonuses on goods

The provisions for bonuses on goods relate to sales campaigns already agreed to with the customers, but not yet implemented. Such provisions are recognized in the statement of income under "Cost of sales".

(c) Contingencies

The Group companies are parties to labor, tax and civil litigation in progress, and are discussing such matters at the administrative and judicial levels, which, when applicable, are supported by judicial deposits. The provisions for probable losses arising from these matters are estimated and periodically adjusted by management, supported by the opinion of its external legal advisors. The provisions are as follows:

	June 30, 2017	December 31, 2016
Labor	2,620	2,903
Civil, social security and tax	909	947
	3,529	3,850

(d) Provision for impairment of trade receivables

As a rule, the Group recognizes the provision for impairment of trade receivables for receivables overdue for more than 180 days and without guarantees (Notes 2(b) and 10).

(e) Provision for inventory losses

The Group recognizes a provision for inventory losses when there is uncertainty regarding the realization of these balances (products with expiry dates approximating their maturity dates and/or damaged products) (Note 11).

(f) Provision for impairment of intangible assets

The Group tests product development balances in intangible assets for impairment, whenever possible through the discounted cash flow method (Notes 2 (g) and 14).

(g) Possible losses, not provided for in the balance sheet

The Group has tax, civil and labor litigation involving risks of loss classified by management as possible, based on the evaluation of the legal advisors, for which no provision for estimated possible losses was recognized. At June 30, 2017, the related proceedings totaled R$ 67,877 (December 31, 2016 - R$ 66,229), and mainly comprised tax (ICMS) and labor claims.

19 Equity

(a) Share capital

At a meeting held on July 12, 2016, the Company's Board of Directors approved a capital increase in the amount of R$ 218, through the issue of 6,699 common shares at the issue price of R$ 32.50 per subscribed share, in connection with the exercise of options of the Stock Option Plan of the Company.

At the Annual and Extraordinary General Meeting held on April 25, 2017, the stockholders approved an increase in the Company's capital of R$ 59,689 without the issue of registered common shares, by incorporating the balance of revenue reserves.

At June 30, 2017, fully subscribed and paid-up capital comprised 53,949,006 common shares without par value.

(b) Capital reserve

As mentioned in Note 1.1, the Company recorded a special goodwill reserve on merger. Considering that the realization of the tax benefit arising from the goodwill is not currently expected, management decided to record a provision in the full amount of the merged balance, with a corresponding entry in the same line item of the special goodwill reserve on merger in which the benefit was initially recorded.

The residual amounts considered as "Capital reserve" related to all expenditures incurred for the Initial Public Offering (IPO).

(c) Allocation of profit

According to the bylaws, profit will be allocated as follows:

- 5% to the legal reserve, limited to 20% of the capital;
- Minimum dividend of 25% of profit adjusted according to article 202 of Law 6,404; and
- The remaining balance will be distributed as resolved at the General Meeting by the stockholders representing not less than 2/3 (two-thirds) of the voting shares, in accordance with applicable legal provisions.

Loss for the year in 2016 was offset against revenue reserves.

All amounts in thousands of reais unless when otherwise stated

(d) Carrying value adjustments

These refer to the effect of the adoption of the deemed cost method to record land in subsidiaries that took place on January 1, 2009, as well as to all foreign exchange rate differences resulting from the translation of the balance sheet and profit or loss of foreign subsidiaries.

(e) Stock option plan

The Group has a Stock Option Plan ("Plan") in place, aiming at: (i) stimulating the Company's growth, success and achievement of objectives; (ii) aligning the interests of the Company's stockholders with those of the eligible individuals; (iii) enabling attracting and retaining professionals and service providers, thus stimulating the generation of value for the Company, and (iv) sharing risks and gains equally among stockholders, management and employees.

The plan is managed by the Board of Directors and, according to its rules, the following are eligible as beneficiaries: members of management, employees and service providers of the Company or of other companies under its control. The total number of common shares for which options may be granted cannot exceed 1.5% of the total common shares of the Company's capital stock. Data on the Company's Stock Option Plan is available at the Brazilian Securities Commission (CVM).

The vesting period considers that the beneficiaries may exercise their right in installments of 1/5 (one fifth) of the total shares granted as from the end of the first year from the date of the signature of the Adhesion Agreement, and the same number of shares annually up to the end of the fifth year, provided that the beneficiaries remain continually linked to the Company.

The exercise price will be set based on the average price of the quotations of the Company's shares on the BM&FBOVESPA, weighted by the trading volume, within the 60 (sixty) trading sessions prior to the grant, monetarily restated for inflation according to the General Market Price Index (IGP-M).

The maximum term for the exercise of these options is 4 (four) years as from the end of the vesting period. Options not exercised according to the terms and conditions established will be automatically canceled, without any compensation.

At December 30, 2014, the Board of Directors defined those elected for the first grant, totaling 809,135 stock options, distributed among 17 beneficiaries, as follows:

					Vesting period closing
	12/31/2015	**12/31/2016**	**12/31/2017**	**12/31/2018**	**12/31/2019**
Number of options	161,827	161,827	161,827	161,827	161,827
Exercise price at launch (strike price)	28.22	28.22	28.22	28.22	28.22
Fair value of options granted	9.65	11.16	12.48	13.74	14.90
Maximum exercise date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023

On September 28, 2016, the Board of Directors approved the grant of 40,000 stock options.

All amounts in thousands of reais unless when otherwise stated

	Vesting period closing				
	9/28/2017	**9/28/2018**	**9/28/2019**	**9/28/2020**	**9/28/2021**
Number of options	8,000	8,000	8,000	8,000	8,000
Exercise price at launch (strike price)	39.38	39.38	39.38	39.38	39.38
Fair value of options granted	12.89	14.87	16.62	18.23	19.66
Maximum exercise date	9/28/2021	9/28/2022	9/28/2023	9/28/2024	9/28/2025

The fair value attributed to the options granted was determined using the Black-Scholes-Merton pricing model, which takes into consideration the value of the share, the exercise price, the time to elapse up to the exercise of the option, the likelihood of the option to be exercised, the historical volatility, the dividend rate and the risk-free interest rate, according to the assumptions below:

	General assumptions and information on the evaluation				
Vesting period closing	**12/31/2015**	**12/31/2016**	**12/31/2017**	**12/31/2018**	**12/31/2019**
Price of the share on the grant date	30.61	30.61	30.61	30.61	30.61
Estimated exercise price (strike price)	33.45	35.41	37.46	39.35	41.38
Estimated life time (in years)	3.0	4.0	5.0	6.0	7.0
Expected volatility	26.20%	26.20%	26.20%	26.20%	26.20%
Risk-free interest rate	12.80%	12.60%	12.40%	12.30%	12.20%

	General assumptions and information on the evaluation				
Vesting period closing	**9/28/2017**	**9/28/2018**	**9/28/2019**	**9/28/2020**	**9/28/2021**
Price of the share on the grant date	39.00	39.00	39.00	39.00	39.00
Estimated exercise price (strike price)	41.57	43.91	46.40	49.07	51.91
Estimated life time (in years)	3.0	4.0	5.0	6.0	7.0
Expected volatility	30.40%	30.40%	30.40%	30.40%	30.40%
Risk-free interest rate	11.60%	11.60%	11.70%	11.70%	11.80%

In the six-month period ended June 30, 2017, expenses amounting to R$ 655 (June 30, 2016 - R$ 863) for stock options were recognized.

Changes in stock options are shown below:

	Number of options	
	June 30, 2017	**June 30, 2016**
Balance at the beginning of the period	679,225	772,723
Number of options canceled (i)	(362,372)	
Balance at the end of the period	316,853	772,723

(i) Refers to terminated employees whose options were canceled as provided for by the Plan's regulations.

All amounts in thousands of reais unless when otherwise stated

20 Revenue (consolidated)

The reconciliation between gross sales and services and net revenue is as follows:

	2017		2016	
	Quarter	**6-month period**	**Quarter**	**6-month period**
Domestic customers				
Gross sales and services	134,594	219,204	141,946	244,478
Taxes and deductions on sales	(13,714)	(28,134)	(18,507)	(32,167)
	120,880	191,070	123,439	212,311
Foreign customers				
Gross sales	17,287	22,521	11,244	20,402
Taxes and deductions on sales	(235)	(473)	(92)	(92)
	17,052	22,048	11,152	20,310
	137,932	213,118	134,591	232,621

21 Costs and expenses by nature

	Parent company			
	2017		2016	
	Quarter	**6-month period**	**Quarter**	**6-month period**
General and administrative expenses				
Personnel expenses	468	883	413	761
Outsourced services	78	153	152	287
Travel expenses	3	5	5	7
Other	212	299	349	432
	761	1,340	919	1,487

All amounts in thousands of reais unless when otherwise stated

	Consolidated			
	2017		2016	
	Quarter	6-month period	Quarter	6-month period
Cost of sales				
Variable costs (raw and consumption materials)	37,416	55,259	39,459	67,448
Personnel expenses	15,890	22,145	12,474	21,322
Depreciation and amortization	4,800	8,099	3,447	6,591
Outsourced services	4,311	6,156	3,515	6,008
Provision for inventory losses	1,717	6,184	506	1,198
Electricity	1,697	2,417	1,669	2,853
Provision for impairment of intangible assets	(279)	(279)		111
Other	1,717	2,741	4,589	6,009
	67,269	102,722	65,659	111,540
Selling expenses				
Personnel expenses	16,884	32,824	16,637	34,963
Sales team expenses	10,695	19,755	12,854	23,885
Outsourced services	4,952	8,723	4,268	7,671
Freight charges	5,204	8,199	4,147	6,954
Provision for impairment of trade receivables	155	148	2,437	5,773
Depreciation and amortization	1,230	2,454	1,216	2,399
Telecommunications and electricity	334	680	360	711
Other	720	2,598	1,755	4,817
	40,174	75,381	43,674	87,173
General and administrative expenses				
Personnel expenses	6,676	14,048	8,727	15,591
Outsourced services	1,386	2,593	1,049	1,681
Depreciation and amortization	957	1,864	859	1,748
Travel expenses	256	431	329	556
Telecommunications and electricity	226	488	200	403
Vehicle expenses	26	115	42	161
Donations and sponsorship	31	156	63	86
Other	601	1,103	976	1,449
	10,159	20,798	12,245	21,675
	117,602	198,901	121,578	220,388

All amounts in thousands of reais unless when otherwise stated

22 Other income (expenses), net

	Parent company			
	2017		2016	
	Quarter	6-month period	Quarter	6-month period
Gains on sales of scrap, rentals and other	23	46	22	45
Federal, state and municipal taxes and fees	(8)	(10)	(2)	(6)
	15	36	20	39

	Consolidated			
	2017		2016	
	Quarter	6-month period	Quarter	6-month period
Gains on sale and write-off of PP&E	84	159	(163)	(110)
Gains on sale of intangible assets (*)	2,677	2,677		
Gains (losses) on sales of scrap, rentals and other	(219)	778	(9)	153
Federal, state and municipal taxes and fees	(63)	(277)	29	(362)
Other losses	(449)	(863)	(139)	(148)
	2,030	2,474	(282)	(467)

(*) Refers to the sale of product registration.

23 Finance income and costs

	Parent company			
	2017		2016	
	Quarter	6-month period	Quarter	6-month period
Finance income				
Income from financial investments		13		3
Monetary variation		1	1	12
Other				(1)
		14	1	14
Finance costs				
Other	(11)	(23)	(11)	(21)
	(11)	(23)	(11)	(21)
Finance result	(11)	(9)	(10)	(7)

All amounts in thousands of reais unless when otherwise stated

				Consolidated
		2017		2016
	Quarter	6-month period	Quarter	6-month period
Finance income				
Income from financial investments	1,608	2,652	507	1,052
Interest receivable	182	410	208	422
Monetary variation		13		41
Other	15	28	32	107
	1,805	3,103	747	1,622
Finance costs				
Interest payable	(3,319)	(6,787)	(2,011)	(4,002)
Finance charges	(914)	(1,356)	(340)	(673)
Other	(137)	(290)	(298)	(615)
	(4,370)	(8,433)	(2,649)	(5,290)
Derivative financial instruments, net				
Losses on derivatives (foreign exchange variation)	4,302	892	(9,112)	(17,702)
Losses on derivatives (interest)	(1,661)	(3,953)	(2,648)	(4,652)
	2,641	(3,061)	(11,760)	(22,354)
Foreign exchange variations, net	(2,842)	(232)	6,854	14,576
Finance result	(2,766)	(8,623)	(6,808)	(11,446)

24 Income tax and social contribution expense or benefit

The income tax and social contribution expense or benefit is reconciled to the standard rates as shown below:

				Parent company
		2017		2016
	Quarter	6-month period	Quarter	6-month period
Profit before income tax and social contribution	13,110	6,216	4,454	1,114
Standard rates	34%	34%	34%	34%
	(4,457)	(2,113)	(1,514)	(379)
Reconciliation to the effective rate:				
Permanent differences:				
Equity in the results of investees	4,715	2,560	1,823	873
Deferred taxes, not recorded	(258)	(447)	(309)	(494)
Income tax and social contribution				

	Consolidated			
	2017		2016	
	Quarter	6-month period	Quarter	6-month period
Profit before income tax and and social contribution	19,594	8,068	5,923	320
Standard rates	34%	34%	34%	34%
	(6,662)	(2,743)	(2,014)	(109)
Reconciliation to the effective rate:				
Permanent differences:				
RD&I benefit	218	218		
Adjustment related to the calculation of subsidiary taxed based on the deemed profit method	995	2,279	1,632	2,760
Adjustment related to the calculation of foreign subsidiary taxed based on the rate in effect in that country	(885)	(1,297)	(289)	(888)
Deferred taxes, not recorded	(258)	(447)	(309)	(494)
Other permanent differences	37	39	(517)	(529)
Income tax and social contribution	(6,555)	(1,951)	(1,497)	740
Reconciliation with the statement of income:				
Current	(594)	(1,326)	(234)	(2,954)
Deferred	(5,961)	(625)	(1,263)	3,694
	(6,555)	(1,951)	(1,497)	740

25 Earnings per share

(a) Basic

Basic earnings per share is calculated by dividing the profit attributable to the stockholders of the Company by the weighted average number of common shares during the period.

	2017		2016	
	Quarter	6-month period	Quarter	6-month period
Profit for the period attributable to owners of the parent	13,110	6,216	4,454	1,114
Weighted average number of common shares in the period	53,949	53,949	53,942	53,942
Basic earnings per share (R$)	0.24301	0.11522	0.08257	0.02065

All amounts in thousands of reais unless when otherwise stated

(b) Diluted

Diluted earnings per share is calculated by dividing the profit attributable to the stockholders of the Company by the weighted average number of common shares during the period, adjusted by the weighted average number of instruments with dilutive effects.

	2017		2016	
	Quarter	6-month period	Quarter	6-month period
Profit for the period attributable to owners of the parent	13,110	6,216	4,454	1,114
Weighted average number of common shares in the period considering instruments with dilutive effects	53,679	53,639	54,151	54,111
Diluted earnings per share (R$)	0.24423	0.11589	0.08225	0.02059

26 Employee benefits

(a) Private pension plan - defined contribution

The Group companies sponsor a defined contribution pension plan for their employees. The plan was implemented in August 2008 and is managed by Itaú Vida e Previdência S.A. The companies' contributions to the plan during the six-month period ended June 30, 2017 totaled R$ 368 (June 30, 2016 - R$ 591).

(b) Profit sharing

The Group companies offer to their employees a variable remuneration program, calculated based on quantitative and qualitative goals established by management. During the six-month period ended June 30, 2017, the amount of the profit-sharing provision was R$ 4,142 (June 30, 2016 - R$ 733).

27 Balances and transactions with related parties

(a) Main balances and transactions

					Parent company
	June 30, 2017		December 31, 2016		
	Current assets	Current liabilities	Current assets	Non-current assets	Current liabilities
	Other assets (i)	Other liabilities (i)	Other assets (i)	Other assets (i)	Other liabilities (i)
Related parties:					
Ouro Fino Saúde Animal Ltda.		19			24
Ouro Fino Agronegócio Ltda.			21		
Ouro Fino Pet Ltda.			6		
Ouro Fino Química Ltda.	92		42		
Stockholders		17			17
Other				165	
	92	36	69	165	41

All amounts in thousands of reais unless when otherwise stated

	Parent company			
	Main transactions:			
	June 30, 2017		June 30, 2016	
	Royalties	Reimburse-ment of CSC expenses (i)	Royalties	Reimburse-ment of CSC expenses (i)
Related parties:				
Ouro Fino Saúde Animal Ltda.		(135)		(183)
Ouro Fino Agronegócio Ltda.		(1)		8
Ouro Fino Pet Ltda.				3
Ouro Fino Química Ltda.	50		50	
	50	(136)	50	(172)

	Consolidated						
	June 30, 2017			December 31, 2016			
	Current assets	Current liabilities		Current assets	Non-current assets	Current liabilities	
	Other assets (i)	Borrowings (ii)	Other liabilities (i)	Other assets (i)	Other assets (i)	Borrowings (ii)	Other liabilities (i)
Related parties:							
Ouro Fino Part. e Empreendimentos S.A.	31			16			
Ouro Fino Química Ltda.	331			278			110
Condomínio Rural Ouro Fino	4			9			
BNDES Participações S.A.		68,172				39,609	
Stockholders			127				77
Other					165		168
	366	68,172	127	303	165	39,609	355

	Consolidated									
	Main transactions:									
	June 30, 2017					June 30, 2016				
	Gross profit on the sales of goods	Reimburse-ment of CSC expenses (i)	Royalties	Other expenses, net	Finance result	Gross profit on the sales of goods	Reimburse-ment of CSC expenses (i)	Royalties	Other expenses, net	Finance result
Related parties:										
Ouro Fino Part. e Empreendimentos S.A.		7					8		38	
Ouro Fino Química Ltda.		1,208	50	(275)			1,413	50	(307)	
Condomínio Rural Ouro Fino	5			(711)		13			(687)	
Stockholders				(12)						
BNDES Participações S.A.					(2,270)					(66)
	5	1,215	50	(998)	(2,270)	13	1,421	50	(956)	(66)

(i) Other assets and liabilities

The other assets and liabilities are represented by the reimbursement of expenses, especially incurred in the Shared Services Center ("CSC"), according to the expense sharing agreement entered into on June 30, 2014.

All amounts in thousands of reais unless when otherwise stated

(ii) Borrowings

These refer to borrowings from the related party BNDES Participações S.A., under conditions similar to those adopted in transactions with third parties (Note 17).

(b) Key management compensation

Key management personnel include members of the Board of Directors and officers appointed pursuant to the Company's bylaws, whose compensation is approved at the Annual General Meeting. The compensation paid or payable to key management for their services is described below:

	June 30, 2017	June 30, 2016
Salaries	984	1,553
Labor charges	184	128
Share-based payments	98	298
Variable compensation	93	140
Compensation and fringe benefits	62	120
Indemnity paid		1,765
	1,421	4,004

Despite the fact that management does not consider share-based payments as compensation, the amounts under this heading are recorded in this Note, as required by the Technical Pronouncement CPC 05 - Related-party Disclosures.

28 Insurance

At June 30, 2017, the Group had insurance coverage for operating risks and comprehensive civil liability, with a maximum indemnity of R$ 420,000.

Section F - Accounting policies

29 Summary of significant accounting policies

The main accounting policies applied in the preparation of this interim accounting information are set out below. These policies have been consistently applied to the periods presented, unless otherwise stated.

29.1 Consolidation

The following accounting policies are applied in the preparation of the accounting information.

(a) Subsidiaries are all entities over which the Group has control. Subsidiaries are fully consolidated from the date on which control is transferred to the Group and deconsolidated from the date that control ceases.

Identifiable assets acquired and liabilities and contingent liabilities assumed for the acquisition of subsidiaries in a business combination are measured initially at their fair values at the acquisition date. Acquisition-related costs are expensed as incurred.

(b) Transactions, balances and unrealized gains between Group companies are eliminated. Unrealized losses are also eliminated, unless the transaction provides evidence of impairment of the asset transferred. The accounting policies of subsidiaries have been changed, where necessary, to ensure consistency with the policies adopted by the Group.

29.2 Foreign currency translation

(a) Functional and presentation currency

Items included in the accounting information of each of the Group companies are measured using the currency of the primary economic environment in which the entities operate (the "functional currency"), which is substantially the Brazilian real, except as mentioned in item (c) below. Therefore, the parent company and consolidated accounting information is presented in this currency.

(b) Transactions and balances

Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions or valuation, when items are measured. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in the statement of income within finance income or cost.

(c) Group companies with a functional currency different from the Brazilian real

The results and the financial position of Ouro Fino de México, S.A. de CV and Ouro Fino Colômbia S.A.S (subsidiaries of Ouro Fino Saúde Animal Ltda.), whose functional currency is different from the presentation currency are translated into the presentation currency as follows:

(i) Assets and liabilities for each balance sheet presented are translated at the closing rate at the date of that balance sheet.

(ii) Income and expenses for each statement of income are translated at the average exchange rates (unless this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the rate on the dates of the transactions).

(iii) All resulting foreign exchange differences are recognized as a separate component of equity, in the account "Carrying value adjustments".

29.3 Financial assets

29.3.1 Classification

The Group classifies its financial assets, upon initial recognition, in the following categories: loans and receivables and measured at fair value through profit or loss. The classification depends on the purpose for which the financial assets were acquired.

(a) Loans and receivables

Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market, and which are not classified in the "at fair value through profit or loss" category. They are included in current assets, except for maturities greater than 12 months after the end of the reporting period, which are classified as non-current assets. Loans and receivables comprise trade and other receivables and cash and cash equivalents in the balance sheet.

(b) Financial assets at fair value through profit or loss

Financial assets at fair value through profit or loss are financial assets held for trading. A financial asset is classified in this category if acquired principally for the purpose of selling in the short-term. All financial assets in this category are classified as current assets. Derivatives are also classified as "held for trading".

29.3.2 Recognition and measurement

Normal purchases and sales of financial assets are recognized on the trade date. Financial assets carried at fair value through profit or loss are initially recognized at fair value, and transaction costs are expensed in the statement of income. Financial assets are derecognized when the rights to receive cash flows have expired or have been transferred and the Company has transferred substantially all the risks and rewards of ownership. Financial assets at fair value through profit or loss are subsequently carried at fair value.

Loans and receivables are carried at amortized cost using the effective interest rate method.

29.3.3 Impairment of financial assets

Assets carried at amortized cost

Management assesses at the balance sheet date whether there is objective evidence that a financial asset or group of financial assets is impaired. A financial asset or a group of financial assets is impaired and impairment losses are incurred only if there is objective evidence of impairment as a result of one or more events that occurred after the initial recognition of the asset (a "loss event") and that loss event (or events) has an impact on the estimated future cash flows of the financial asset or group of financial assets that can be reliably estimated.

29.4 Derivative financial instruments

Derivative financial instruments are contracted with the purpose of hedging transactions against the risks of fluctuations in foreign exchange and interest rates, and are not used for speculative purposes. The Group mainly operates with exchange rate and interest rate swap contracts. Derivatives are recognized at fair value on the date a derivative contract is entered into and are subsequently remeasured at their fair value. Since the Group does not adopt hedge accounting, the changes in the fair value of derivative instruments are recognized immediately in the statement of income within "Finance income and costs".

29.5 Trade receivables

Trade receivables are stated at the original sales amount, plus, when applicable, monetary and foreign exchange variations, and less the provision for impairment of trade receivables. If collection is expected in one year or less, the receivables are classified as current assets. If not, they are presented as non-current assets.

29.6 Inventories

Inventories are stated at the lower of average cost of purchase or production and net realizable value. Cost is determined using the weighted average fixed method. The cost of finished products and work in process comprises raw materials, direct labor, other direct costs and related general production expenses (based on the normal operational capacity). Net realizable value is the estimated selling price in the ordinary course of business, less estimated completion costs and estimated selling expenses. Imports in transit are stated at the accumulated cost of each transaction.

29.7 Current and deferred income tax and social contribution

The income tax and social contribution expenses for the period comprise current and deferred taxes. Income taxes are recognized in the statement of income, except to the extent that they relate to items recognized directly in equity. In this case, the taxes are also recognized directly in equity.

The current and deferred income tax and social contribution are calculated on the basis of the tax laws enacted at the balance sheet date in the countries where the Group entities operate and generate taxable income. The currently defined tax rates in Brazil of 25% for income tax and 9% for social contribution are utilized to calculate deferred taxes.

The current and deferred income tax and social contribution are presented net, separated by taxpaying entity, in liabilities when there are amounts payable, or in assets when the amounts prepaid exceed the total amount due on the reporting date.

Deferred income tax and social contribution are recognized on accumulated tax losses and temporary differences between the tax bases of assets and liabilities and their carrying amounts in the accounting information. They are determined based on tax rates in effect on the balance sheet date and which are expected to apply when the related deferred tax asset is realized or the deferred tax liability is settled.

Deferred tax assets are recognized only to the extent it is probable that future taxable profit will be available against which the temporary differences and/or tax losses can be utilized.

Ouro Fino Pet Ltda. calculates income tax and social contribution under the deemed profit method. The deemed profit system is a simplified taxation method to determine the calculation basis of corporate entities that are not required, in the calendar year, to use the taxable profit method, or whose total gross revenue is equal to or lower than R$ 78,000.

29.8 Intangible assets

(a) Research and development of products

Research expenditures are recognized as expenses when incurred. Expenditures incurred in the development of products are recognized as intangible assets only if the cost can be reliably measured and when it is probable that they will bring future economic benefits.

The Group evaluates projects based on its own methodology, which considers various analysis structures, and the projects will be successful from the development of "pilots" of the products made according to the requirements of regulatory bodies, accompanied by analyses of financial feasibility.

Capitalized development expenditures are amortized as from the beginning of the sale of the product, using the straight-line method over the period of the expected benefit, which is, on average, 10 years.

The finance charges on borrowings to finance a project are capitalized during the period required to develop the products.

(b) Trademarks and licenses purchased

Separately purchased trademarks and licenses are initially stated at historical cost. Since trademarks and licenses have a defined useful life, they are subsequently carried at cost less accumulated amortization. Amortization is calculated using the straight-line method over the estimated useful lives of approximately 10 years.

Trademarks and licenses acquired in a business combination are recognized at fair value at the acquisition date. Amortization is calculated using the straight-line method over the estimated useful lives of between 10 and 18 months.

(c) Software

Computer software licenses acquired are capitalized on the basis of the costs incurred to acquire and bring to use the specific software. These costs are amortized over their estimated useful lives of five years on the straight-line method.

Costs associated with maintaining computer software are recognized as an expense, as incurred.

(d) Goodwill on the acquisition of subsidiaries

Goodwill arises from the acquisition of subsidiaries and represents the excess of (i) the consideration transferred, and (ii) the acquisition-date fair value of identifiable assets acquired and liabilities assumed. Goodwill on acquisitions of subsidiaries is recorded as "Intangible assets" in the consolidated accounting information. Goodwill is tested annually for impairment and carried at cost less accumulated impairment losses. Impairment losses on goodwill are not reversed. Gains and losses on the disposal of an entity include the carrying amount of goodwill relating to the entity sold.

29.9 Property, plant and equipment

Property, plant and equipment are stated at historical cost adjusted in subsidiaries to reflect the deemed cost of land on the date of transition to IFRS, less accumulated depreciation. Depreciation is calculated on the straight-line method, considering the estimated useful lives of the respective assets. The annual depreciation rates are disclosed in Note 15. Subsequent costs are included in an asset's carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably. The carrying amount of the replaced part or item is derecognized. All other repairs and maintenance are charged to the statement of income when incurred.

If the carrying amount of an asset is higher than its recoverable value, the Group records a provision for impairment to adjust the carrying amount to the estimated recoverable value.

The costs of borrowings used to finance the construction of property, plant and equipment are capitalized during the period necessary to construct and prepare the asset for its intended use.

Gains and losses on disposal are determined by comparing the proceeds with the carrying amount and are recognized within "Other income (expenses), net" in the statement of income.

29.10 Impairment of non-financial assets

Assets that are subject to amortization are reviewed for impairment whenever events or changes in circumstances indicate that their carrying amount may not be recoverable. An impairment loss is recognized when the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value less costs to sell and its value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows.

29.11 Trade payables

Trade payables are obligations to pay for goods or services that have been acquired in the ordinary course of business and are classified as current liabilities if payment is due in one year or less. If not, they are presented as non-current liabilities.

Accounts payable are recognized initially at fair value and subsequently measured at amortized cost using the effective interest rate method. In practice, they are usually recorded at the amount of the related invoice.

29.12 Borrowings

Borrowings are initially recognized on the receipt of funds, net of transaction costs, and are subsequently presented at cost plus charges and interest in proportion to the period elapsed, using the effective interest rate method.

Borrowings are classified as current liabilities unless the Company has an unconditional right to defer settlement of the liability for at least 12 months after the reporting period.

29.13 Employee benefits

(a) Private pension plan

The Group companies sponsor a defined contribution pension plan for their employees. In the defined contribution plan, the companies pay contributions to private pension plans on contractual bases. After the contributions have been made, the companies have no further obligations for additional payments. The regular contributions comprise the net periodic costs for the period in which they are due and are included in personnel expenses.

(b) Profit sharing

The provisions are calculated based on quantitative and qualitative targets established by management and are recorded as personnel expenses in the statement of income.

(c) Share-based payments

The Company has one share-based compensation plan (stock option plan), duly approved by the Board of Directors, under which it receives services from its executives and third parties as consideration for the stock options granted. The premium for these options, calculated on the grant date, is recognized as an expense, against equity, during the vesting period.

29.14 Revenue recognition

Revenue comprises the fair value of the consideration received or receivable for the sale of products and services in the ordinary course of the activities. Revenue is shown net of value-added tax, returns, rebates and discounts, and after eliminating sales within the Group. Revenue is recognized when the amount of revenue can be reliably measured and when it is probable that future economic benefits will result from the transaction. The Group bases its estimates on historical results, taking into consideration the type of customer, the type of transaction and the specifics of each arrangement.

Sales revenues are adjusted to reflect the effects of a significant financing component when it is expected, at the beginning of the contract, that the period between the sale of products and services and the time the customer pays for those products or services exceeds one year. Where applicable, the adjustment to present value in long-term sales transactions has a corresponding entry in "Trade receivables" and its realization is recorded in "Finance income," according to maturity.

29.15 Distribution of dividends and interest on capital

The distribution of dividends and interest on capital to stockholders is recognized as a liability in the accounting information based on the Company's bylaws. Any amount that exceeds the minimum required is only provisioned on the date it is approved by the stockholders at the Ordinary General Meeting.

The tax benefit of interest on capital is recognized in the statement of income, because in substance it represents a decrease in the effective rate of income tax and social contribution.

29.16 New standards that are not yet effective

The following new standards were issued by IASB but are not effective for the six-month period ended June 30, 2017. The early adoption of standards, even though encouraged by IASB, has not been implemented in Brazil by the Brazilian Accounting Pronouncements Committee (CPC).

- IFRS 9 - "Financial instruments": addresses the classification, measurement and recognition of financial assets and financial liabilities. The complete version of IFRS 9 was issued in July 2014, and is effective as from January 1, 2018. It replaces the orientation included in IAS 39 related to the classification and measurement of financial instruments. The main amendments brought by IFRS 9 are: (i) new criteria for the classification of financial assets; (ii) new impairment model for financial assets, which is a hybrid of expected and incurred losses, replacing the current model of incurred losses; and (iii) relaxation of the requirements for adoption of the hedge accounting. Management is evaluating the full impact of adopting IFRS 9.

- IFRS 15 - "Revenue from Contracts with Customers": this new standard replaces IAS 11, "Construction Contracts", IAS 18, "Revenue" and related interpretations and introduces the principles to be applied by an entity to determine the measurement and recognition of revenue. This standard is based on the principle that revenue is recognized when the control of a good or service is transferred to a customer, so the control principle will replace the principle of risks and rewards. Effective date is January 1, 2018. Management is evaluating the full impact of adopting IFRS 15.

- IFRS 16 - "Leases": the new standard requires lessees to recognize the liability of the future payments and the right of use of the leased asset for virtually all lease contracts, including operating leases. Certain short-term and low-value contracts may be out of the scope of this new standard. The criteria for recognition and measurement of leases in the accounting information of the lessors are substantially maintained. IFRS 16 is effective for years beginning on or after January 1, 2019 and replaces IAS 17 - "Leases" and corresponding interpretations. Management is evaluating the full impact of adopting IFRS 16.

There are no other IFRSs or IFRIC interpretations that are not yet effective that would be expected to have a material impact on the Group.

* * *